A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Viatris Inc. is a global healthcare company focused on providing access to medicines, operating primarily in the generic pharmaceuticals, branded generics, biosimilars, and select innovative specialty medicines markets. The company develops, manufactures, and distributes a broad portfolio of prescription medicines across multiple therapeutic areas, with revenues primarily driven by off-patent and complex generic products sold at scale to healthcare systems, pharmacies, and governments.
Viatris was formed in 2020 through the combination of Mylan N.V. and Upjohn, a legacy off-patent branded medicines business previously owned by Pfizer Inc. The merger created one of the world’s largest suppliers of generic and branded medicines by volume, positioning Viatris as a key player in global drug accessibility with a diversified product base and broad geographic reach.
Business Operations
Viatris operates through a single, integrated global business model rather than formally segmented reporting units, with revenue generated from the sale of pharmaceuticals across developed and emerging markets. Its portfolio includes oral solid doses, injectables, complex generics, biosimilars, and branded products addressing cardiovascular disease, infectious diseases, oncology, central nervous system disorders, and autoimmune conditions. Key products include branded medicines such as EpiPen, Lipitor, and Lyrica, alongside a large base of generic equivalents.
The company maintains vertically integrated operations, controlling manufacturing, research and development, quality assurance, and global distribution. Viatris operates numerous manufacturing facilities and R&D centers worldwide and leverages long-standing commercial relationships with wholesalers, retail pharmacies, hospitals, and public health agencies. The company also maintains strategic collaborations for biosimilars development and commercialization.
Strategic Position & Investments
Viatris’ strategy centers on cash generation, portfolio optimization, and disciplined capital allocation, with an emphasis on reducing leverage while selectively investing in complex generics, biosimilars, and differentiated medicines. The company has pursued divestitures of non-core assets and localized product portfolios to streamline operations and focus on higher-margin opportunities.
Notable transactions include the divestiture of certain developed market brands and regional businesses, as well as continued investment in biosimilars such as Semglee (insulin glargine). Viatris also retains stakes in joint ventures, including Biocon Biologics, supporting its long-term exposure to biosimilars and emerging biologic therapies.
Geographic Footprint
Viatris operates in more than 165 countries and territories, with a strong presence across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. The company is headquartered in Pittsburgh, Pennsylvania, and maintains regional hubs in India, Europe, and Greater China.
Emerging markets represent a significant portion of Viatris’ revenue base, reflecting its strategic focus on access-driven healthcare systems and high-volume demand. The company’s global manufacturing and supply chain infrastructure supports both local market needs and international distribution, reinforcing its role as a critical supplier to national healthcare systems worldwide.
Leadership & Governance
Viatris is led by an experienced executive team with backgrounds spanning global pharmaceuticals, finance, and operations. The leadership emphasizes operational discipline, patient access, and long-term value creation through sustainable cash flows and portfolio focus.